pharma · Hypertension · Breast Neoplasms
Pfizer
Pfizer is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Hypertension, Breast Neoplasms, Complicated Intra-abdominal Infection, Non-Small Cell Lung Cancer, Arthritis, Rheumatoid
Company details
- Status
- Public
- HQ
- New York 10017, US
- Employees
- 103,316
- Programs
- 98
- Drugs
- 80
- Patents
- 0
Quick answer
Pfizer is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Hypertension, Breast Neoplasms, Complicated Intra-abdominal Infection, Non-Small Cell Lung Cancer, Arthritis, Rheumatoid. NovaPharmaNews links 98 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (58), approved (15), phase 1 (13).
Company snapshot
Pfizer maintains 98 tracked programs across Hypertension, Breast Neoplasms, Complicated Intra-abdominal Infection, Non-Small Cell Lung Cancer, Arthritis, Rheumatoid, Metastatic Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Rheumatoid Arthritis, Migraine, Pulmonary Arterial Hypertension, Chronic Low Back Pain With a Neuropathic Component. Momentum score: 32/100 (30-day d
- 98 active pipeline program(s) linked via ClinicalTrials.gov.
- 98 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Pfizer. Not investment advice.
Recent coverage
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
This plan organizes a tightly sourced Eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Pfizer.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Pfizer.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Pfizer?
-
Is Pfizer publicly traded?
-
What drugs does Pfizer develop or market?
-
What are the latest developments for Pfizer?
-
What therapeutic areas does Pfizer focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.